Andrew Quick is the Chief Technology Officer at AVITA Medical Inc.
As the Chief Technology Officer of AVITA Medical Inc, the total compensation of Mr Quick at AVITA Medical Inc is $491,697. There are 2 executives at AVITA Medical Inc getting paid more, with Dr. Michael S. Perry D.V.M., DVM, FACVPT, Ph.D. having the highest compensation of $1,058,847.
Mr Quick is 50, he's been the Chief Technology Officer of AVITA Medical Inc since . There are 4 older and 1 younger executives at AVITA Medical Inc. The oldest executive at AVITA Medical Inc is Dr. Michael S. Perry D.V.M., DVM, FACVPT, Ph.D., 62, who is the CEO, Pres & Exec. Director.
Andrew's mailing address filed with the SEC is C/O AVITA MEDICAL, INC., 28159 AVENUE STANFORD, SUITE 220, VALENCIA, CA, 91355.
Over the last 5 years, insiders at AVITA Medical Inc have traded over $2,850,472 worth of AVITA Medical Inc stock and bought 19,459 units worth $293,310 . The most active insiders traders include Michael S Perry, James Corbett e David D O'toole. On average, AVITA Medical Inc executives and independent directors trade stock every 82 days with the average trade being worth of $135,636. The most recent stock trade was executed by David D O'toole on 30 May 2024, trading 1,000 units of RCEL stock currently worth $8,900.
avita medical (http://www.avitamedical.com/) is a publicly listed regenerative medicine company trading on the australian stock exchange (asx:avh) and otc markets (otcqx:avmxy). the company’s lead product, recell® is used in a wide variety of burns, chronic wounds, plastic, reconstructive and cosmetic procedures. recell is patented, ce-marked for europe, tga- registered in australia, and sfda-cleared in china. recell is not available for sale in the united states; in the us recell is an investigational device limited by federal law to investigational use.
AVITA Medical Inc executives and other stock owners filed with the SEC include: